Ministry of Food and Drug Safety approves GC Green Cross Wellbeing’s COVID-19 treatment clinical trial

Input 2021.02.26 17:59

‘Rineekju’, a treatment for steatitis–

–

The Ministry of Food and Drug Safety announced on the 26th that it has approved a phase 2 clinical trial plan for a novel coronavirus infection (Corona 19) treatment for GC Green Cross Wellbeing’s placental injection’Linekju’.

Lineeju is an injection of a specialized drug used to improve liver function in patients with steatohepatitis. It is made from substances obtained from the human placenta. In cell and animal experiments, Rineek has been found to have the effect of reducing the amount of corona19 virus and alleviating symptoms.

With the approval that day, there were 14 candidate drugs in clinical trials as a treatment for Corona 19 in Korea. On the 5th, after Celltrion’s’Rekironaju’ was first approved by the Ministry of Food and Drug Safety, Chong Kun Dang (185750), GCGreen Cross (006280), Daewoong Pharmaceutical (069620)Etc. are also preparing to apply for permission.

–

– .

Related posts:

"A sense of proportion instead of drawing board education"

Yamaha NMAX 160 Flat Deck: A Stunning and Feature-Packed Scooter for the Indonesian Market

Challenges Faced by Departmental Councils in Recovering Social Accommodation Assistance through Lega...

Supreme Court Revokes Slander Conviction for Lawyer Accusing Judge of Prevarication